Loading cancer entity…
Loading cancer entity…
Variants & evidence
1,206 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR L718V2 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | D | Supports Resistance | 2 | submitted | EID8069Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with erlotinib suppressed phosphorylation of EGFR L858R+C797S but did not decrease phosphory… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC | civic |
| Osimertinib | Lung Adenocarcinoma | Predictive | D | Supports Resistance | 3 | submitted | EID8059A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC | civic |
| EGFR L747_A750delinsP5 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2550In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2551A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell Carcinoma | |||||||
| EGFR L747P1 | ||||||||
| Erlotinib + GefitinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Does Not Support Sensitivity Response | 2 | accepted | EID4220In a study, 2 participants with stage IV adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have L747P mutation and were treated with the 1st generation TKIs gefitinib … (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC | civic |
| EGFR L747_P753delinsS9 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2610In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2611A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Erlotinib | Lung Adenocarcinoma | |||||||
| EGFR L747_P753>Q5 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2599In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2600A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell Carcinoma | |||||||
| EGFR L747_S752del7 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2154A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Erlotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID3796A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC) PMID 19671843 · Jackman et al., 2009 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell Carcinoma | |||||||
| EGFR L747_S752delinsQ1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID4667EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient … (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| EGFR L747_T751delinsP6 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2581In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2582A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell Carcinoma | |||||||
| EGFR L747_T751delinsQ5 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2561In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2562A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell Carcinoma | |||||||
| EGFR L747_T751delLREAT5 | ||||||||
| Afatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2554In a study of 585 non-small cell lung cancer patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2590A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell Carcinoma | |||||||
| EGFR L792H1 | ||||||||
| Osimertinib | Lung Adenocarcinoma | Predictive | D | Supports Resistance | 2 | submitted | EID8079A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R+T790M transgene. Twenty of 49 mice treated with osimertinib developed treatment-resistant tum… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC | civic |
| EGFR H835L + EGFR L833V1 | ||||||||
| Firmonertinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID13093Two patients with advanced lung adenocarcinoma harboring the EGFR L833V/H835L compound mutation received first-line furmonertinib (80 mg once daily), and both achieved partial responses according to R… (full text at CIViC) PMID 40963567 · Wang et al., 2025 · Open in CIViC | civic |
| EGFR L838P1 | ||||||||
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID4252In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L838P mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC | civic |
| EGFR L858R1 | ||||||||
| (prognostic) | Lung Non-Small Cell CarcinomaCURATED_BROADER | Prognostic | B | Supports Better Outcome | 3 | accepted | EID347Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR. PMID 24662454 · Douillard et al., 2014 · Open in CIViC | civic |
Data updated 16 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID2545In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC |
| civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2546In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2549In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID4270In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L747_P753insS mutation was associated with resistance to erlotinib treatment. The patient surv… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC |
| civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | accepted | EID4266In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L8… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | submitted | EID4267In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment (IC50=0.006�M), comparable to Ba/F3 cells expressing EGFR L858R (a known s… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC | civic |
| Afatinib + ErlotinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID5944Ba/F3 cells transduced with EGFR delL747_P753insS were IL3 growth independant, suggesting driver mutation, and demonstrated sensitivity to erlotinib treatment (growth inhibition IC50=0.006 micro molar… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2605In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2606In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2609In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID2594In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC |
| civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2595In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2598In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID3798In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was tre… (full text at CIViC) PMID 27569104 · Kocoglu et al., 2016 · Open in CIViC |
| civic |
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2149In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2150In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2151EGFR exon 19 deletion mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a Phase 2 clinical trial, lun… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2152In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID2576In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC |
| civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2577In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2578In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR… (full text at CIViC) PMID 19692680 · Mok et al., 2009 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2580In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID2556In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC |
| civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2557In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2560In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID2588In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC |
| civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2589In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | rejected | EID2603In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC | civic |